Subtype
Renal Cell Carcinoma
CI-CAN-00006578RCCExplore in graph →
375 active trials17 approved drugs60 evidence items
Loading cancer entity…
Subtype
CI-CAN-00006578RCCExplore in graph →
Clinical trials
1,621 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (276)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07689240 | Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma | not yet recruiting | Phase 3 | 400 | National Cancer Institute (NCI)NIH | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07165418 | A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI | not yet recruiting | Phase 3 | 116 | Peking University Cancer Hospital & InstituteOTHER |
| 1 |
| Sep 10, 2025 |
| clinicaltrials |
| NCT06146777 | Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy | not yet recruiting | Phase 3 | 468 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Nov 29, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jul 8, 2026source: clinicaltrials